CoQ10

Phase 2Small molecule

UUniversity of Kansas Medical Center

CoQ10 is one of 73 small molecule programs targeting Fatigue. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diastolic Heart FailureActive, not recruiting

Oxidative StressActive, not recruiting

Breast CancerActive, not recruiting

Diastolic Heart FailurePhase 2

Active, not recruiting

Oxidative StressPreclinical

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

CoQ10

UUniversity of Kansas Medical Center

Phase 2

1 4

Voltaren

Novartis

Preclinical

1 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Tricor

JJagotec

Preclinical

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 9

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease1 trial

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

Completed·UUniversity of Rochester·Phase 2·NCT00076492·195 enrolled

Diastolic Heart Failure1 trial

CoQ10 and D-ribose in Patients With Diastolic Heart Failure

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT03133793·216 enrolled

Huntington's Disease1 trial

Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)

Completed·JJohns Hopkins University·Phase 2·NCT00920699·90 enrolled

Coenzyme Q101 trial

Effects of Coenzyme Q10 in PSP and CBD

Completed·LLahey Clinic·Phase 2/3·NCT00532571

Breast Cancer1 trial

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Completed·—·Phase 1·NCT00976131·7 enrolled

2 more indications

Oxidative Stress1 trial

Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients

Unknown status·MMaimónides Biomedical Research Institute of Córdoba·N/A·NCT02218476·50 enrolled

Fatigue1 trial

Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study

Enrolling by invitation·UUniversity of Pennsylvania·Phase 1·NCT06419335·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CoQ10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CoQ10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CoQ10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kansas Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Kansas Medical Center

CoQ10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson's Disease1 trial

Diastolic Heart Failure1 trial

Huntington's Disease1 trial

Coenzyme Q101 trial

Breast Cancer1 trial

Oxidative Stress1 trial

Fatigue1 trial

References

Drug Info

Quick Facts

Related News